M. Hage

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

L. Ronco, B. V. van Engelen, D. Cadavid, 2021, British journal of clinical pharmacology.

c-Jun NH2-Terminal Kinase Activity in Subcutaneous Adipose Tissue but Not Nuclear Factor-κB Activity in Peripheral Blood Mononuclear Cells Is an Independent Determinant of Insulin Resistance in Healthy Individuals

M. Cooper, B. Kingwell, B. de Courten, 2009, Diabetes.

Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement (1557)

L. Ronco, B. Engelen, D. Cadavid, 2020 .